Free Trial

OncoCyte (OCX) Competitors

$3.30
+0.01 (+0.30%)
(As of 07/17/2024 ET)

OCX vs. ACHL, DRRX, VNRX, TKNO, ABIO, ICCC, TRIB, AWH, CDIO, and BMRA

Should you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Achilles Therapeutics (ACHL), DURECT (DRRX), VolitionRx (VNRX), Alpha Teknova (TKNO), ARCA biopharma (ABIO), ImmuCell (ICCC), Trinity Biotech (TRIB), Aspira Women's Health (AWH), Cardio Diagnostics (CDIO), and Biomerica (BMRA). These companies are all part of the "medical" sector.

OncoCyte vs.

OncoCyte (NASDAQ:OCX) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

In the previous week, OncoCyte had 3 more articles in the media than Achilles Therapeutics. MarketBeat recorded 4 mentions for OncoCyte and 1 mentions for Achilles Therapeutics. Achilles Therapeutics' average media sentiment score of 1.88 beat OncoCyte's score of 0.22 indicating that Achilles Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
OncoCyte Neutral
Achilles Therapeutics Very Positive

Achilles Therapeutics has a net margin of 0.00% compared to OncoCyte's net margin of -2,905.14%. Achilles Therapeutics' return on equity of -42.95% beat OncoCyte's return on equity.

Company Net Margins Return on Equity Return on Assets
OncoCyte-2,905.14% -135.45% -48.68%
Achilles Therapeutics N/A -42.95%-37.88%

Achilles Therapeutics received 11 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 54.84% of users gave Achilles Therapeutics an outperform vote while only 8.00% of users gave OncoCyte an outperform vote.

CompanyUnderperformOutperform
OncoCyteOutperform Votes
6
8.00%
Underperform Votes
69
92.00%
Achilles TherapeuticsOutperform Votes
17
54.84%
Underperform Votes
14
45.16%

OncoCyte has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.

OncoCyte presently has a consensus target price of $4.06, indicating a potential upside of 23.11%. Achilles Therapeutics has a consensus target price of $4.00, indicating a potential upside of 365.71%. Given Achilles Therapeutics' higher possible upside, analysts plainly believe Achilles Therapeutics is more favorable than OncoCyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OncoCyte
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
Achilles Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

55.4% of OncoCyte shares are held by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are held by institutional investors. 1.9% of OncoCyte shares are held by insiders. Comparatively, 5.4% of Achilles Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

OncoCyte has higher revenue and earnings than Achilles Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncoCyte$1.50M18.19-$27.78MN/AN/A
Achilles TherapeuticsN/AN/A-$69.67M-$1.60-0.54

Summary

Achilles Therapeutics beats OncoCyte on 10 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCX vs. The Competition

MetricOncoCyteDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$27.22M$2.90B$5.31B$8.64B
Dividend YieldN/A0.70%2.80%3.98%
P/E RatioN/A91.27122.1715.20
Price / Sales18.1972.582,142.7077.89
Price / CashN/A18.4035.2734.07
Price / Book1.333.924.974.55
Net Income-$27.78M$30.88M$110.56M$216.32M
7 Day Performance4.76%6.85%2.75%3.56%
1 Month Performance22.68%2.81%9.37%7.91%
1 Year Performance-25.71%-26.33%5.79%2.45%

OncoCyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACHL
Achilles Therapeutics
2.5529 of 5 stars
2.55 / 5 stars
$0.84
flat
$4.00
+376.5%
-16.0%$34.50MN/A-0.52204Positive News
DRRX
DURECT
3.1316 of 5 stars
3.13 / 5 stars
$1.31
-2.2%
$27.50
+1,999.2%
-71.1%$40.66M$8.55M-1.3858Short Interest ↑
VNRX
VolitionRx
1.2829 of 5 stars
1.28 / 5 stars
$0.64
+1.6%
$2.50
+287.7%
N/A$53.48M$770,000.00-1.40110Analyst Forecast
TKNO
Alpha Teknova
2.7925 of 5 stars
2.79 / 5 stars
$1.24
+1.6%
$5.00
+303.2%
-45.9%$50.62M$36.68M-1.18210Insider Buying
News Coverage
Gap Down
High Trading Volume
ABIO
ARCA biopharma
0.3181 of 5 stars
0.32 / 5 stars
$3.32
-3.5%
N/A+71.1%$48.17MN/A-7.904Upcoming Earnings
Analyst Upgrade
News Coverage
Positive News
Gap Up
ICCC
ImmuCell
0 of 5 stars
0.00 / 5 stars
$4.22
+0.7%
N/A-18.4%$32.96M$17.47M-8.2774Short Interest ↓
TRIB
Trinity Biotech
0.9315 of 5 stars
0.93 / 5 stars
$2.76
-4.2%
N/A-29.6%$21.03M$56.83M-0.99380Gap Up
AWH
Aspira Women's Health
1.9918 of 5 stars
1.99 / 5 stars
$1.27
+7.6%
$4.45
+250.4%
-61.8%$15.81M$9.15M-0.8864Short Interest ↑
Gap Down
High Trading Volume
CDIO
Cardio Diagnostics
2.0076 of 5 stars
2.01 / 5 stars
$0.55
flat
$2.00
+263.6%
-52.9%$12.48M$20,000.000.007Positive News
Gap Down
BMRA
Biomerica
0 of 5 stars
0.00 / 5 stars
$0.37
-12.0%
N/A-74.5%$6.17M$5.34M-0.9962Positive News

Related Companies and Tools

This page (NASDAQ:OCX) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners